Rothschild & Co. Asset Management US Inc. purchased a new position in shares of Avanos Medical Inc (NYSE:AVNS) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 16,855 shares of the company’s stock, valued at approximately $719,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of Montreal Can boosted its holdings in Avanos Medical by 26.7% during the 4th quarter. Bank of Montreal Can now owns 3,648 shares of the company’s stock valued at $164,000 after acquiring an additional 768 shares during the period. Suntrust Banks Inc. boosted its holdings in Avanos Medical by 32.6% during the 4th quarter. Suntrust Banks Inc. now owns 5,080 shares of the company’s stock valued at $228,000 after acquiring an additional 1,248 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Avanos Medical during the 1st quarter valued at about $230,000. Advisor Group Inc. boosted its holdings in Avanos Medical by 64.4% during the 4th quarter. Advisor Group Inc. now owns 5,414 shares of the company’s stock valued at $242,000 after acquiring an additional 2,120 shares during the period. Finally, LS Investment Advisors LLC boosted its holdings in Avanos Medical by 89.3% during the 4th quarter. LS Investment Advisors LLC now owns 5,659 shares of the company’s stock valued at $253,000 after acquiring an additional 2,670 shares during the period. Institutional investors and hedge funds own 93.44% of the company’s stock.
AVNS stock opened at $41.10 on Monday. The company has a current ratio of 2.77, a quick ratio of 2.22 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 50.12 and a beta of 1.41. Avanos Medical Inc has a 1 year low of $38.00 and a 1 year high of $72.96.
A number of brokerages recently commented on AVNS. Zacks Investment Research cut Avanos Medical from a “hold” rating to a “sell” rating in a report on Monday, May 6th. ValuEngine cut Avanos Medical from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Morgan Stanley set a $47.00 target price on Avanos Medical and gave the company a “sell” rating in a report on Wednesday, May 8th. Finally, KeyCorp lowered their target price on Avanos Medical from $67.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, February 27th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. Avanos Medical has an average rating of “Hold” and a consensus target price of $63.00.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Read More: Back-End Load
Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical Inc (NYSE:AVNS).
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.